logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Cost-effectiveness analysis of a rotavirus immunization program for the United States.

    Article - En anglais

    Context-Rotavirus is the most common cause of severe diarrhea in children, and a live, oral vaccine may soon be licensed for prevention.

    Objective

    To estimate the economic impact of a national rotavirus immunization program in the United States.

    Design-Cost-effectiveness was analyzed from the perspectives of the health care system and society.

    A decision tree used estimates of disease burden, costs, vaccine coverage, efficacy, and price obtained from published and unpublished sources.

    Intervention-The proposed vaccine would be administered to infants at ages 2,4, and 6 months as part of the routine schedule of childhood immunizations.

    Main Outcome Measures-Total costs, outcomes prevented, and incremental cost-effectiveness.

    Results

    A routine, universal rotavirus immunization program would prevent 1.08 million cases of diarrhea, avoiding 34 000 hospitalizations, 95 000 emergency department visits, and 227 000 physician visits in the first 5 years of life.

    At $20 per dose, the program would cost $289 million and realize a net loss of $107 million to the health care system-$103 per case prevented.

    The program would provide a net savings of $296 million to society.

    Threshold analysis identified a break-even price per dose of $9 for the health care system and $51 for the societal perspective.

    Greater disease burden and greater vaccine efficacy and lower vaccine price increased cost-effectiveness. (...)

    Mots-clés Pascal : Etats Unis, Amérique du Nord, Amérique, Programme sanitaire, Prévention, Analyse coût efficacité, Coût global, Immunisation active, Vaccination, Rotavirus, Reoviridae, Virus, Diarrhée, Economie santé, Politique sanitaire, Nourrisson, Homme, Appareil digestif pathologie, Intestin pathologie

    Mots-clés Pascal anglais : United States, North America, America, Sanitary program, Prevention, Cost efficiency analysis, Life cycle cost, Active immunization, Vaccination, Rotavirus, Reoviridae, Virus, Diarrhea, Health economy, Health policy, Infant, Human, Digestive diseases, Intestinal disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0261404

    Code Inist : 002B30A03B. Création : 11/09/1998.